IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Sold by Siemens Fonds Invest GmbH

Siemens Fonds Invest GmbH lowered its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 78.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 563 shares of the company's stock after selling 2,103 shares during the period. Siemens Fonds Invest GmbH's holdings in IDEXX Laboratories were worth $241,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Norges Bank bought a new stake in shares of IDEXX Laboratories in the 4th quarter valued at about $412,258,000. Flossbach Von Storch SE grew its holdings in IDEXX Laboratories by 5,439.3% during the fourth quarter. Flossbach Von Storch SE now owns 473,336 shares of the company's stock valued at $195,696,000 after purchasing an additional 464,791 shares during the period. Alyeska Investment Group L.P. purchased a new position in IDEXX Laboratories in the 4th quarter valued at approximately $156,412,000. William Blair Investment Management LLC raised its position in shares of IDEXX Laboratories by 701.6% in the fourth quarter. William Blair Investment Management LLC now owns 422,133 shares of the company's stock worth $174,527,000 after buying an additional 369,471 shares in the last quarter. Finally, BNP Paribas Financial Markets lifted its stake in IDEXX Laboratories by 221.3% during the fourth quarter. BNP Paribas Financial Markets now owns 441,319 shares of the company's stock worth $182,459,000 after purchasing an additional 303,966 shares during the last quarter. Institutional investors own 87.84% of the company's stock.

Insider Buying and Selling at IDEXX Laboratories

In related news, Director M Anne Szostak sold 1,260 shares of IDEXX Laboratories stock in a transaction on Wednesday, May 21st. The stock was sold at an average price of $512.34, for a total transaction of $645,548.40. Following the transaction, the director now directly owns 1,801 shares in the company, valued at approximately $922,724.34. The trade was a 41.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 0.98% of the stock is currently owned by corporate insiders.

IDEXX Laboratories Stock Performance

NASDAQ IDXX traded down $3.03 on Friday, reaching $512.52. The stock had a trading volume of 1,221,827 shares, compared to its average volume of 652,599. The company has a market cap of $41.22 billion, a P/E ratio of 48.03, a price-to-earnings-growth ratio of 3.41 and a beta of 1.52. IDEXX Laboratories, Inc. has a 1-year low of $356.14 and a 1-year high of $530.60. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95. The firm has a fifty day moving average of $449.80 and a two-hundred day moving average of $437.27.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The company reported $2.96 EPS for the quarter, topping analysts' consensus estimates of $2.93 by $0.03. The firm had revenue of $998.43 million during the quarter, compared to analyst estimates of $998.25 million. IDEXX Laboratories had a return on equity of 55.82% and a net margin of 22.78%. The company's revenue for the quarter was up 3.6% on a year-over-year basis. During the same period in the previous year, the company posted $2.71 EPS. On average, equities research analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the stock. Bank of America raised their price target on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the company a "neutral" rating in a research report on Tuesday, February 4th. Stifel Nicolaus lifted their price objective on shares of IDEXX Laboratories from $460.00 to $510.00 and gave the company a "hold" rating in a report on Monday, May 19th. Piper Sandler boosted their price objective on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the stock a "neutral" rating in a research note on Monday, February 10th. Morgan Stanley increased their price target on shares of IDEXX Laboratories from $548.00 to $558.00 and gave the stock an "overweight" rating in a report on Monday, May 5th. Finally, Wall Street Zen lowered IDEXX Laboratories from a "buy" rating to a "hold" rating in a research report on Friday. Four research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $536.00.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.